v3.24.3
Condensed Consolidated Interim Balance Sheet - USD ($)
$ in Thousands
Sep. 30, 2024
Jun. 30, 2024
Current assets    
Cash and cash equivalents $ 3,020 $ 4,909
Prepaid expenses, taxes and other receivables 258 414
Clinical trial deposit 205 205
Total current assets 3,483 5,528
Property and equipment, net 657 674
Total assets 4,140 6,202
Current liabilities    
Accounts payable and accrued liabilities 2,207 2,207
Total current liabilities 2,257 2,259
Milestone payment liability 188 186
Total liabilities 2,445 2,445
Stockholders' equity    
Common stock Authorized 75,000 shares at September 30, 2024 (June 30, 2024 - 75,000), $0.001 par value, Issued and outstanding 1,590 issued at September 30, 2024 (June 30, 2024 - 1,579) 2 2
Additional paid-in capital 163,445 153,358
Accumulated deficit (162,052) (159,876)
Accumulated other comprehensive income 21 21
Total stockholders' equity 1,695 3,757
Total liabilities and stockholders' equity 4,140 6,202
Related Party    
Current liabilities    
Related party payables 50 52
Preferred Stock Series A    
Stockholders' equity    
Preferred stock $ 279 279
Preferred Stock Series C    
Stockholders' equity    
Preferred stock   $ 9,973

Source